arrow
K

Klaus Pantel

Institute of Tumor Biology
H指数:138
被引数:8.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting common denominators of DNA damage tolerance mechanisms as therapeutic strategy to cope with dynamic phenotypic changes in triple-negative breast cancer cells

靶向DNA损伤耐受机制的共同分母作为应对三阴性乳腺癌细胞动态表型变化的疗法策略

2026-10-060
OAAI
Editorial Expression of Concern: Tumour exosome integrins determine organotropic metastasis

编者关注声明:肿瘤外泌体整合素决定器官趋向性转移

Nature
IF48.5
2026-08-050
PRE
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer

循环肿瘤细胞中的染色体不稳定性与转移性去势抵抗性前列腺癌中的卡巴他赛耐药性

2025-12-220
OA
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy

SURVIVE HERoes研究方案(NCT06643585):曲妥珠单抗德鲁替康用于HER2阳性/低表达早期乳腺癌在一线治疗后出现分子复发且ctDNA阳性的患者

2025-11-190
PRE
Perspectives in educating molecular pathologists on liquid biopsy: Toward integrative, equitable, and decentralized precision oncology

分子病理学家液体活检教育的视角:迈向整合、公平和去中心化的精准肿瘤学

2025-11-010
OAAI
Fast enrichment and detection of circulating tumor cells from large volumes of whole blood of breast cancer patients utilizing a functionalized bioaffinity CTC filtration membrane

利用功能化生物亲和性CTC过滤膜,快速富集和检测来自乳腺癌患者大量全血中的循环肿瘤细胞

2025-10-270
OAAI
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors

SURVIVE研究(NCT05658172):将乳腺癌随访护理带入21世纪:一项比较液体活检指导与标准护理监测对中高风险乳腺癌幸存者效果的III期临床试验研究方案

2025-09-090
OAAI